Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 777-784

  Giaccone, Giuseppe ^a   Herbst, Roy S ^b   Manegold, Christian ^b   Scagliotti, Giorgio ^b   Rosell, Rafael ^b   Miller, Vincent ^b   Natale, Ronald B ^b   Schiller, Joan H ^b   Von Pawel, Joachim ^b   Pluzanska, Anna ^b   Gatzemeier, Ulrich ^b   Grous, John ^b   Ochs, Judith S ^b   Averbuch, Steven D ^b   Wolf, Michael K ^b   Rennie, Pamela ^b   Fandi, Abderrahim ^b   Johnson, David H ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEFITINIB; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE;

ACNE; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRY SKIN; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; STANDARDIZATION; THROMBOCYTOPENIA; VOMITING; ADULT; AGED; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; LUNG TUMOR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; QUINAZOLINES; REFERENCE VALUES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542503746     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.001     Document Type: Article

References (23)

1. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
2. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
3. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12-18, 1999
4. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130, 2000
5. Baselga J: New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1:12-21, 2000
6. Wells A: The epidermal growth factor receptor (EGFR): A new target in cancer therapy. Signal 1:4-11, 2000
7. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
8. Douillard J-Y, Giaccone G, Horai T, et al: Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1195)
9. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
10. Natale RB, Skarin A, Maddox A-M, et al: Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1167)
11. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
12. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
13. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
14. Gonzalez-Larriba JL, Giaccone G, van Oosterom A, et al: ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: Final results of a phase I trial. Proc Am Soc Clin Oncol 21:95a, 2002 (abstr 376)
15. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: Results from a phase III clinical trial - INTACT 2. J Clin Oncol 22:785-794, 2004
16. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
17. World Medical Association Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925-926, 1997
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
19. Rom DM, Costello RJ, Connell LT: On closed test procedures for dose-response analysis. Stat Med 13:1583-1596, 1994
20. Herbst R, Giaccone G, Schiller J, et al: Subset analyses of INTACT results for gefitinib ('Iressa', ZD1839) when combined with platinum-based chemotherapy for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 22:627, 2003 (abstr 2523)
21. Inoue A, Saijo Y, Maemondo M. et al: Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139, 2003
22. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 7:31-39, 2002 (suppl 4)
23. Bailey LR, Kris M, Wolf M, et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pre-treated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44:1362, 2003 (abstr LB-170)